iScience (Sep 2023)

Structural characterization of an isocytosine-specific deaminase VCZ reveals its application potential in the anti-cancer therapy

  • Wenting Guo,
  • Xiaojia Li,
  • Jingyu Fan,
  • Hongwei Li,
  • Yan Wen,
  • Chunyan Meng,
  • Haitao Chen,
  • Zhipeng Zhao,
  • Yuling Zhang,
  • Yushen Du,
  • Baixing Wu

Journal volume & issue
Vol. 26, no. 9
p. 107672

Abstract

Read online

Summary: Non-natural nucleobase isocytosine (IC) is the isomer of cytosine; its chemical derivate 5-fluoroisocytosine (5-FIC) together with the isocytosine-specific deaminase (ICD) VCZ was suggested to be potential practical enzyme/prodrug pair for cancer therapy through gene-directed enzyme-prodrug therapy (GDEPT) method. In this study, we have determined the crystal structures of apo-VCZ and its complex with 5-FU. We identified the critical residues for substrate binding and catalytic reaction. We also captured the substrate-induced conformational changes of VCZ, then proposed the conjectural reaction procedures of VCZ for converting the IC into the uracil. Moreover, we evaluated the therapeutic effect of wildtype or the mutated VCZ protein in the colorectal cancer cell lines. Our studies will shed light on optimizing the ICD/5-FIC pairs by modifying either the enzyme or the prodrug based on the structural observations, thereby improving the possibility of applying the ICD/5-FIC pair in clinical trials.

Keywords